Long‐term follow‐up of 3‐month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial
Authors:
Open Access
- 5 January 2010
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 105 (2) , 185-190
Abstract
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE: To report our long‐term follow‐up of an institutional randomized prospective trial of radical prostatectomy (RP) with or without a 3‐month course of neoadjuvant hormone therapy (NHT), which results in pathological downstaging, but generally no reduction in biochemical recurrence (BCR) on early follow‐up (at 3 years). PATIENTS AND METHODS: From December 1992 to June 1996, 148 patients with clinically localized prostate cancer were randomized to RP only or 3 months of goserelin acetate and flutamide before RP. BCR was defined as a detectable serum prostate specific antigen level (>0.1 ng/mL) at least 6 weeks after surgery, with a confirmatory increase. RESULTS: The median follow‐up for BCR‐free patients was 8 years. There was no significant difference in BCR‐free probabilities between groups ( P = 0.7). The BCR‐free probability at 7 years was 78% for patients undergoing RP only and 80% for patients undergoing NHT and RP (difference of 2%; 95% confidence interval, CI, 12–16%). A Cox regression showed no significant relationship between NHT and BCR (hazard ratio 1.16; 95% CI, 0.56–2.39, P = 0.7). Overall, two patients had local recurrence and six developed metastases, and were evenly distributed among the RP only and NHT groups. CONCLUSION: Although our study was not originally powered to detect differences in BCR, there was no overall benefit in BCR‐free probability, local recurrence or metastasis with 3 months of NHT at 8 years of follow‐up. Pending evidence of improvement in patient outcomes, NHT before RP appears to be unjustified outside of clinical trials.Keywords
This publication has 35 references indexed in Scilit:
- Do Margins Matter? The Prognostic Significance of Positive Surgical Margins in Radical Prostatectomy SpecimensJournal of Urology, 2008
- Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancerCochrane Database of Systematic Reviews, 2006
- Neo-adjuvant and adjuvant hormone therapy for localised prostate cancer2006
- Long-term Followup of a Randomized Trial of 0 Versus 3 Months of Neoadjuvant Androgen Ablation Before Radical ProstatectomyJournal of Urology, 2003
- NEOADJUVANT HORMONAL ABLATIVE THERAPY BEFORE RADICAL PROSTATECTOMY: A REVIEW. IS IT INDICATED?Journal of Urology, 2000
- 4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate CancerEuropean Urology, 2000
- Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate CancerJournal of Urology, 1996
- Randomized Study of Neoadjuvant Testicular Androgen Ablation Therapy Before Radical Prostatectomy in Men with Clinically Localized Prostate CancerJournal of Urology, 1996
- Biochemical and Pathological Effects of 8 Months of Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy in Patients with Clinically Confined Prostate CancerJournal of Urology, 1996
- Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate CancerJournal of Urology, 1995